Drug intelligence / Profile preview

laosixietai

Development stage: Unknown
Lead developer: China Medical System
Modality: Peptides
Administration: Intravenous

Overview

Laosixietai (also known as CMS024) is a synthetic 14-amino acid polypeptide developed by Kangzhe Pharmaceutical Research (Shenzhen) Co., Ltd. It is being investigated as an anti-tumor therapeutic for the treatment of advanced non-small cell lung cancer (NSCLC), particularly in patients who have failed second- or third-line therapies. The drug is administered via injection and has undergone Phase II clinical evaluation in China. While its precise molecular target has not been publicly disclosed, it is characterized as a peptide-based agent with potential immunomodulatory and anti-proliferative properties intended to inhibit tumor progression in late-stage cancer patients.

Other names: 劳斯协泰

Beyond the preview

Go deeper on laosixietai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on laosixietai.

Explore the full profile